Latest news
-
-
August 8, 2016
Almac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology
-
June 8, 2016
Almac Diagnostic Services Expand Companion Diagnostic Development Service Offering with NanoString Barcoding Technology
-
March 8, 2016
Almac Group Opens Additional Companion Diagnostic Laboratory in Durham NC USA
-
November 12, 2015
Almac Group to Collaborate with Illumina on Next-Generation Sequencing Based Companion Diagnostic Development
-
July 10, 2015
Almac Group Announce Companion Diagnostic Partnerships with OncoMed
-
March 3, 2015
Almac Group Appoints Dr. Shirin Khambata Ford as VP Product Development
-
February 5, 2015
Almac Appoints VP Quality and Regulatory Affairs
-
January 28, 2014
Data Presented Supporting Almac Developed Colon Signature as a Significant Predictor of Risk of Recurrence in Stage II Colon Cancer